or Login to see your representatives.

Access Candidates' and Representatives' Biographies, Voting Records, Interest Group Ratings, Issue Positions, Public Statements, and Campaign Finances

Simply enter your zip code above to get to all of your candidates and representatives, or enter a name. Then, just click on the person you are interested in, and you can navigate to the categories of information we track for them.

[x] close
Print Track This Candidate

Public Statements

Representative Henry A. Waxman's Public Statements on Drugs

Henry Waxman
Full Name: Henry A. Waxman
Office: U.S. House (CA) - District 33, Democratic
First Elected: 1974
Last Elected: 11/06/2012
Next Election: 2014
Gender: Male
Family: Wife: Janet; 2 Children: Michael, Shai
Birth Date: 09/12/1939
Birth Place: Los Angeles, CA
Home City: Los Angeles, CA
Religion: Jewish

Issue



(clear issue)

Keyword Search

Date Title Location
Oct. 9, 2012 Letter to Chairman Upton, Chairman Pitts, and Chairman Stearns Unknown
March 8, 2012 Hearing of the Health Subcommittee of the House Energy and Commerce Committee - "FDA User Fees 2012: Hearing on Issues Related to Accelerated Approval, Medical Gas, Antibiotic Development and Downstream Pharmaceutical Supply Chain Washington, DC
March 1, 2012 Hearing of the Commerce, Manufacturing, and Trade Subcommittee of the House Energy and Commerce Committee - Prescription Drug Diversion: Combating the Scourge Washington, DC
Feb. 17, 2012 Letter to The Honorable Margaret A. Hamburg, Commissioner U.S. Food and Drug Administration Unknown
Feb. 9, 2012 Members Introduce Bipartisan Legislation to Improve FDA Generic Drug Approvals Washington, DC
Feb. 9, 2012 Hearing of the Health Subcommittee of the House Energy and Commerce Committee - "Review of the Proposed Generic Drug and Biosimilars, User Fees and Further Examination of Drug Shortages" Washington, DC
Feb. 9, 2012 Bipartisan Group of Members Introduce Legislation to Improve Access to Lower Cost Generic Drugs Unknown
Jan. 13, 2012 Rep. Waxman Statement on Generic Drug and Biosimilar User Fee Programs Unknown
Dec. 7, 2011 Synthetic Drug Control Act of 2011 Washington, DC
Oct. 13, 2011 Letter to The Honorable Patty Murray Chairwoman and The Honorable Jeb Hensarling Chairman Joint Select Committee for Deficit Reduction Unknown
Sept. 23, 2011 Hearing of the Health Subcommittee of the House Energy and Commerce Committee - "Examining the Increase in Drug Shortages" Washington, DC
Sept. 23, 2011 Rep. Waxman Statement on GAO Report on Drug Pricing Unknown
Sept. 9, 2011 Letter to The Honorable Jon Leibowitz Chairman Federal Trade Commission Unknown
June 16, 2011 House Democratic Leaders Introduce Legislation to Save More Than $100 Billion in Medicare Drug Costs Unknown
June 1, 2011 House Appropriations Committee Passes Bill to Weaken Critical FDA Public Health Functions Unknown
April 14, 2011 Hearing of the Commerce, Manufacturing, and Trade Subcommittee of the House Energy and Commerce Committee - "Warning: The Growing Danger of Prescription Drug Diversion" Washington, DC
April 13, 2011 Hearing of the Oversight and Investigations Subcommittee of the House Energy and Commerce Committee - "Import Safety: Status of FDA's Screening Efforts at the Border" Washington, DC
April 12, 2011 Dingell, Waxman, Pallone, & DeGette Introduce Drug Safety Enhancement Act Washington, DC
March 28, 2011 Letter to The Honorable Margaret Hamburg Commissioner U.S. Food and Drug Administration Unknown
March 24, 2011 Letter to Mr. Gregory J. Divis President Ther-Rx Corporation Chief Executive Officer KV Pharmaceutical Company Unknown
March 14, 2011 New GAO Report Highlights Importance of Health Care Reform Law's Medicare Drug Savings for Seniors Unknown
March 4, 2011 Letter to The Honorable Joseph R. Pitts Chairman Subcommittee on Health Unknown
Dec. 17, 2010 Dingell, Waxman, Pallone, & Stupak Introduce Drug Safety Legislation Washington, DC
Sept. 20, 2010 Waxman, Dingell, Pallone & Stupak Open Discussion on Potentially Historic Changes in Drug Safety Laws Unknown
July 22, 2010 Hearing of the Subcommittee on Health of the House Committee on Energy and Commerce - Pending Public Health Legislation Washington, DC
May 28, 2010 Tax Extenders Act of 2009 Washington, DC
March 10, 2010 Hearing Of The Subcommittee On Health Of The House Committee On Energy And Commerce - Drug Safety: An Update From The FDA Washington, DC
Dec. 8, 2009 Hearing Of The Subcommittee On Health Of The House Committee On Energy And Commerce- Prescription Drug Price Inflation: Are Prices Rising Too Fast? Washington, DC
Nov. 3, 2009 Hearing Of The Subcommittee On Commerce, Trade And Consumer Protection Of The House Committee On Energy And Commerce- "The NFL StarCaps Case: Are Sports' Anti-Doping Programs At A Legal Crossroads?" Washington D.C.
June 11, 2009 Hearing Of The Health Subcommittee Of The House Energy And Commerce Committee - Emerging Health Care Issues: Follow-On Biologic Drug Competition Washington, DC
June 10, 2009 Chairman Waxman's Statement on FTC Report on Follow-on Biologic Drug Competition Washington, DC
May 1, 2009 Hearing Of The Health Subcommittee Of The House Energy And Commerce Committee - The 2009 H1N1 Flu Outbreak And The United States Federal Response Washington, DC
March 11, 2009 Bipartisan Group of Members Introduces "Promoting Innovation and Access to Life-Saving Medicines Act" Washington, DC
July 31, 2008 Senate, House Members Introduce Bill to Provide Doctors With Unbiased Information About Prescription Drugs Washington, DC
July 30, 2008 Animal Drug User Fee Amendments of 2008 Washington, DC
May 1, 2008 Panel I of a Hearing of the Health Subcommittee of the House Energy and Commerce Committee - Drug Safety Provisions of the Food and Drug Administration Globalization Act Discussion Draft Legislation Washington, DC
April 2, 2008 Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008 Washington, DC
Sept. 26, 2007 Hearing of the House Subcommittee on Health of the House Committee on Energy and Commerce - H.R. 3610, The Food and Drug Import Saftey Act Washington, DC
Sept. 19, 2007 Food and Drug Administration Amendments Act of 2007 Washington, DC
Sept. 6, 2007 Generic Pharmaceutical Association's 2007 Annual Policy Conference: Generics: Prescription for Affordable Health Care Washington, DC
Aug. 2, 2007 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008 Washington, DC
July 11, 2007 Food and Drug Administration Amendments Act of 2007 Washington, DC
June 6, 2007 Chairman Waxman's Opening Statement Hearing on FDA's Role in Evaluating Safety of Avandia Washington, DC
Dec. 19, 2006 GAO Analysis Refutes Industry Myths About Drug Development Unknown
Sept. 26, 2006 Biodefense and Pandemic Vaccine and Drug Development Act of 2006 Washington, DC
Sept. 5, 2006 Letter to Comptroller General of the United States David M. Walker Unknown
May 4, 2006 Hearing: Continuation of the Hearing on Implementation of the Medicare Drug Benefit Washington, DC
March 14, 2006 Hoyer, Colleagues Call for Extension to Enrollment Period for Medicare Prescription Drug Program Washington, DC
March 9, 2006 Office of National Drug Control Policy Reauthorization Act of 2005 Washington, DC
Feb. 3, 2006 Internal Documents Reveal That Medicare Drug Benefit Is Causing Chaos At Social Security Administartion Unknown

About Project Vote Smart

Help Us If You Can

Media & Communications

Education

For Candidates

One Common Ground, Philipsburg, MT 59858 Hotline: 888-Vote-Smart (888-868-3762)
All content © 1992 - 2013 Project Vote Smart unless otherwise attributed - Privacy Policy - Legislative demographic data provided by Aristotle International, Inc. Mobile Version

Back to top